Macrophage Activation: Dissociation of Cytotoxic Activity from Ia-A Antigen Expression (Fibroblast Interferon/Immune Interferon/Lymphokine) ELLIOTT J

Total Page:16

File Type:pdf, Size:1020Kb

Macrophage Activation: Dissociation of Cytotoxic Activity from Ia-A Antigen Expression (Fibroblast Interferon/Immune Interferon/Lymphokine) ELLIOTT J Proc. Nati. Acad. Sci. USA Vol. 80, pp. 2031-2035, April 1983 Immunology Macrophage activation: Dissociation of cytotoxic activity from Ia-A antigen expression (fibroblast interferon/immune interferon/lymphokine) ELLIOTT J. BLUMENTHAL, WALDEN K. ROBERTS, ADRIANA VASIL, AND DAVID W. TALMAGE Department of Microbiology and Immunology, University of Colorado Health Sciences Center, Denver, Colorado 80262 Contributed by David W. Talmage, December 20, 1982 ABSTRACT Peritoneal macrophages were obtained from MATERIALS AND METHODS DBA/2 mice that were untreated or after the injection of bacillus Cainette-Guerin (BCG), thioglycollate broth, proteose-peptone Mice. Our source of peritoneal macrophages was DBA/2 broth, or gamma-irradiated P-815 tumor cells. These macro- mice that were less than 3 months old (The Jackson Labo- phages were "activated" to become cytotoxic for a fibroblast cell ratory). line (L 929) by the addition of lymphokines (LKs), lipopolysac- Elicitation of Peritoneal Macrophages. Peritoneal exudate charide (LPS), or fibroblast interferon (IFN-.3), and the expres- cells were collected by lavage with 5 ml of sterile Eagle min- sion of I region-associated antigens (Ia-Ad) on the macrophages imal essential medium. Resident cells were removed from un- was examined both before and after activation. Thioglycollate- treated mice. Cells were also obtained (a) 3-4 days after the elicited macrophages became Ia-A' when activated by LKs, but injection of 1 ml of 3% thioglycollate in broth that had been they remained la-A- when activated by LPS or IFN-f3. Resident "aged" for at least 6 months at 40C or (b) 3 days after intra- macrophages and proteose-peptone-elicited macrophages re- peritoneal injection of 1 ml of 1% proteose-peptone broth. mained Ia-A- when activated with LKs. Macrophages from BCG- The bacillus Calmette-Guerin (BCG)-elicited macrophages were infected mice were both Ia-A' and cytotoxic for tumor cells with- induced by injection of 0.1 ml of medium containing 2-3 X out further treatment. In contrast, macrophages from mice in- 107 BCG organisms into the tail vein. Four weeks later, 0.1 jected with gamma-irradiated P-815 mastocytoma cells were Ia- ml of purified protein derivative (2 mg/ml) was injected in- A+ but not cytotoxic, and these macrophages could not be made traperitoneally; 5 days later the exudate cells were removed cytotoxic by incubation with LKs. The cultured macrophage-like by lavage. The P-815-elicited macrophages were induced by cell lines P388D1 and WEHI-3 became Ia-A+ after incubation with intraperitoneal injection of 3 X 106 irradiated (5,000 R; 1 R LKs, and this treatment amplified the cytotoxicity of both cell lines. = 2.58 x 10-4 C/kg); P-815 tumor cells 5-6 days later the We conclude that a number of factors are important in deter- exudate cells were removed by lavage. All of the cell prep- mining whether Ia-A expression accompanies macrophage acti- arations were then washed three times with minimal essential vation and that Ia-A is irrelevant as a surface marker for mac- medium before counting and use. rophage activation. Macrophage Cell Lines. The two macrophage-like cell lines WEHI-3 and P388D1 were generously supplied by John Kap- I region-associated antigens (la) have been detected on distinct pler and Philippa Marrack (National Jewish Hospital and Re- subpopulations of macrophages. Most macrophages from the search Center, Denver, CO). These cells were grown in RPMI spleen, thymus, and liver are la', whereas la- macrophages medium supplemented with 0.5 mM 2-mercaptoethanol, pen- predominate in the peritoneal cavity (1-3). It has been shown icillin, streptomycin, and 10% fetal calf serum. that only the Ia+ subset of macrophages is effective in pre- Production of LKs. The LKs were prepared as described senting antigen to T cells (4, 5). In addition, Ia expression ap- (12). Briefly, spleens were removed from CF1 mice that were pears to be a prerequisite for macrophages to act as accessory infected or had been injected intravenously with 2 X 107 BCG cells for lymphokine (LK) production and lymphocyte prolif- organisms 18 days earlier. To the spleen cell suspension (usu- eration (6, 7). ally 5 x 10' cells per ml) was added concanavalin A (Con A) Recently, it has been demonstrated that LK preparations can (Pharmacia, Uppsala, Sweden) to 5 ,Ag/ml, and the cells were induce la- macrophages to become Ia+ in vitro (8-10). Similar incubated for 2 hr at 370C in a chamber containing 95% air/ of LKs are known to contain 5% CO2. The cells were then collected by centrifugation and preparations macrophage-acti- resuspended in minimal essential medium supplemented as vating factor (MAF) which stimulates macrophages to become above but without Con A, and the incubation was continued cytotoxic for tumor cells (11). This raises the questions of whether for 24 hr. The cells were then removed by centrifugation and the Ia' macrophage is the cytotoxic macrophage and whether the culture supernatants were combined and used as a crude La antigens can be used as a surface marker for macrophage ac- source of MAF and immune interferon (IFN-y). tivation. Purification of IFN-y. The spleen cell culture supernatant In this report, we present evidence indicating that the cy- from the LK preparation was partially purified by ammonium totoxic macrophage can be either Ia-A+ or Ia-A-, depending sulfate precipitation and passed over a Con A-Sepharose col- upon the procedures used for elicitation and activation of it. umn as described (12). Also, Ia-A was found not to be a useful marker for macrophage Assay for Macrophage Activation. The cytotoxicity assay activation because Ia-A expression was neither necessary nor we used for LK activation of macrophages has been described sufficient for macrophage cytotoxicity. Abbreviations: IFN-,B, fibroblast interferon (type I); IFN-y, immune The publication costs of this article were defrayed in part by page charge interferon (type II); LPS, lipopolysaccharide; BCG, bacillus Calmette- payment. This article must therefore be hereby marked "advertise- Guerin; MAF, macrophage-activating factor; LK, lymphokine; Con A, ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. concanavalin A. 2031 Downloaded by guest on September 24, 2021 2032 Immunology: Blumenthal et aL Proc. Natl. Acad. Sci. USA 80 (1983) in detail elsewhere (12, 13). Briefly, mouse L 929 cells were A Zeiss microscope was used to observe the fluorescence labeled with [3H]thymidine, trypsinized, and added to 16-mm of the cells, and photomicrographs were taken on Kodak culture wells of a cluster plate (Costar, Cambridge, MA) at a Ektachrome film (160 ASA tungsten). The exposure time for concentration of 1 x 105 cells per well. After incubation for the fluorescence microscopy under the blue light was 5 min. another 24 hr, a suspension containing 4-10 X 105 peritoneal At least 200 cells were counted for each quantitation, and the macrophages per ml in minimal essential medium containing positive cells were characterized by having good peripheral 10% fetal calf serum was added. Following a 2-hr incubation, staining; the controls did not show any staining. the nonadherent cells were removed and the medium was re- placed with 0.5 ml of LKs diluted in minimal essential me- dium/10% fetal calf serum. These cultures were then incu- RESULTS bated for 48 hr at 370C in 95% air/5% C02, the plates were Effect of LKs on la-Ad Expression by Macrophages. Fig. removed, 5 ul of a 1 mg/ml solution of pancreatic DNase 1 demonstrates how different populations of macrophages stain (Worthington) was added to each well, and the plates were with the anti-Ia-Ad antiserum followed by the fluorescein-la- incubated an additional 20 min at 37TC. This terminal incu- beled anti-mouse globulin antiserum. Cells that did not re- bation with DNase facilitated the release of [3H]thymidine from ceive LKs during the incubation period were not stained (Fig. dead cells. The culture supernatants from each well were then 1A); and LK-induced cells stained brightly (Fig. 1B). We chose added to vials containing 5 ml of Biofluor (New England Nu- the 3-day period for staining the cells because we found that clear) and the radioactivity was determined by liquid scintil- la expression reaches its peak on this day and this correlates lation counting. Normally, <5% of the total radioactivity was with the findings of others (8). When normal mouse serum released in the absence of LKs whereas >50% was released was substituted for the anti-Ia-Ad antiserum in the procedure, when LKs were present during the assay. LK-treated cells appeared similar to those in Fig. IA. In all Antibodies. The hybridoma MK-D6 (anti-Ia-Ad) cell line was cases there were a few stained B cells that reacted directly generously provided by John Kappler and Philippa Marrack. with the goat anti-mouse IgG-fluorescein and thus were pos- The antibody produced by this cell line has been classified as itive in the normal serum controls. They were particularly belonging to the IgG2a class and has been mapped to Ia-Ad plentiful in the resident cell populations (Fig. 1C), but they by its reactivity with BLO.D2 or D2.GD but not BLO.LG. A were easily distinguished from macrophages by their small size. goat anti-mouse fluorescein-conjugated IgG (Meloy, Spring- There was no staining of either resident (Fig. 1C) or proteose- field, VA) was used as an indirect label to quantitate the Ia- peptone-elicited macrophages (Fig. 1D) when cultured for 3 Ad antigens on the macrophages. days in medium containing LKs. All of these macrophage Quantitation of Ia-Ad Antigens.
Recommended publications
  • Correlation of Cytokine Level with the Severity of Severe Fever With
    Liu et al. Virology Journal (2017) 14:6 DOI 10.1186/s12985-016-0677-1 RESEARCH Open Access Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome Miao-Miao Liu1, Xiao-Ying Lei1, Hao Yu2, Jian-zhi Zhang3 and Xue-jie Yu1,4* Abstract Background: Severe fever with thrombocytopenia syndrome (SFTS) was an emerging hemorrhagic fever that was caused by a tick-borne bunyavirus, SFTSV. Although SFTSV nonstructural protein can inhibit type I interferon (IFN-I) production Ex Vivo and IFN-I played key role in resistance SFTSV infection in animal model, the role of IFN-I in patients is not investigated. Methods: We have assayed the concentration of IFN-α, a subtype of IFN-I as well as other cytokines in the sera of SFTS patients and the healthy population with CBA (Cytometric bead array) assay. Results: The results showed that IFN-α, tumor necrosis factor (TNF-α), granulocyte colony-stimulating factor (G-CSF), interferon-γ (IFN-γ), macrophage inflammatory protein (MIP-1α), interleukin-6 (IL-6), IL-10, interferon-inducible protein (IP-10), monocyte chemoattractant protein (MCP-1) were significantly higher in SFTS patients than in healthy persons (p < 0.05); the concentrations of IFN-α, IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10 were significant higher in severe SFTS patients than in mild SFTS patients (p < 0.05). Conclusion: The concentration of IFN-α as well as other cytokines (IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10) is correlated with the severity of SFTS, suggesting that type I interferon may not be significant in resistance SFTSV infection in humans and it may play an import role in cytokine storm.
    [Show full text]
  • Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation
    Review Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation Chiara Rizzo 1, Giulia Grasso 1, Giulia Maria Destro Castaniti 1, Francesco Ciccia 2 and Giuliana Guggino 1,* 1 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology Section, University of Palermo, Piazza delle Cliniche 2, 90110 Palermo, Italy; [email protected] (C.R.); [email protected] (G.G.); [email protected] (G.M.D.C.) 2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-091-6552260 Received: 30 April 2020; Accepted: 29 May 2020; Published: 3 June 2020 Abstract: Primary Sjogren Syndrome (pSS) is a complex, multifactorial rheumatic disease that mainly targets salivary and lacrimal glands, inducing epithelitis. The cause behind the autoimmunity outbreak in pSS is still elusive; however, it seems related to an aberrant reaction to exogenous triggers such as viruses, combined with individual genetic pre-disposition. For a long time, autoantibodies were considered as the hallmarks of this disease; however, more recently the complex interplay between innate and adaptive immunity as well as the consequent inflammatory process have emerged as the main mechanisms of pSS pathogenesis. The present review will focus on innate cells and on the principal mechanisms of inflammation connected. In the first part, an overview of innate cells involved in pSS pathogenesis is provided, stressing in particular the role of Innate Lymphoid Cells (ILCs). Subsequently we have highlighted the main inflammatory pathways, including intra- and extra-cellular players.
    [Show full text]
  • Interactions Between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Auto-Immune Diseases
    Type 1 interferons and the Th17 response in TB 1 http://hdl.handle.net/1765/106444 Interactions between type 1 interferons and the Th17 response in tuberculosis: Lessons learned from auto-immune diseases Bas C. Mourik1, Erik Lubberts2, Jurriaan E.M. de Steenwinkel1, Tom H.M. Ottenhoff3, Pieter J.M. Leenen4* 1Dept.Interactions of Medical Microbiology & between Infectious Diseases, Erasmus type MC, Rotterdam,1 interferons the Netherlands 2Dept.and of Rheumatology, the Th17 Erasmus MC, response Rotterdam, the Netherlands in tuberculosis: 3Dept.2 of Immunology, Erasmus MC, Rotterdam, the Netherlands Lessons learned from auto-immune 4Dept. of Infectious Diseases, LUMC, Leiden, the Netherlands Publisheddiseases in Frontiers in Immunology 2017 Apr 5;8:294. doi: 10.3389/fimmu.2017.00294. eCollection 2017 Bas C. Mourik1, Erik Lubberts2, Jurriaan E.M. de Steenwinkel1, Tom H.M. Ottenhoff3, Pieter J.M. Leenen4* 1Dept. of Medical Microbiology & Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands 2Dept. of Rheumatology, Erasmus MC, Rotterdam, the Netherlands 3Dept. of Immunology, Erasmus MC, Rotterdam, the Netherlands 4Dept. of Infectious Diseases, LUMC, Leiden, the Netherlands Published in Frontiers in Immunology 2017 Apr 5;8:294. doi: 10.3389/fimmu.2017.00294. eCollection 2017 2 Erasmus Medical Center Rotterdam ABSTRACT The classical paradigm of TB immunity, with a central protective role for Th1 responses and IFN-γ-stimulated cellular responses, has been challenged by unsatisfactory results of vaccine strategies aimed at enhancing Th1 immunity. Moreover, preclinical TB models have shown that increasing IFN-γ responses in the lungs is more damaging to the host than to the pathogen. Type 1 interferon signaling and altered Th17 responses have also been associated with active TB, but their functional roles in TB pathogenesis remain to be established.
    [Show full text]
  • Interferon Type I Responses in Primary and Secondary Infections
    Immunology and Cell Biology (2008) 86, 239–245 & 2008 Australasian Society for Immunology Inc. All rights reserved 0818-9641/08 $30.00 www.nature.com/icb REVIEW Interferon type I responses in primary and secondary infections Mohammed Alsharifi, Arno Mu¨llbacher and Matthias Regner The mammalian host responds to a microbial infection with a rapid innate immune reaction that is dominated by type I interferon (IFN-I) release. Most cells of vertebrates can respond to microbial attack with IFN-I production, but the cell type responsible for most of the systemic IFN-I release is thought to be plasmacytoid dendritic cells (pDCs). Besides its anti- microbial and especially anti-viral properties IFN-I also exerts a regulatory role on many facets of the sequential adaptive immune response. One of these is being the recently described partial, systemic activation of the vast majority of B and T lymphocytes in mice, irrespective of antigen reactivity. The biological significance of this partial activation of lymphocytes is at present speculative. Secondary infections occurring within a short time span of a primary infection fail to elicit a similar lymphocyte activation response due to a refractory period in systemic IFN-I production. This period of exhaustion in IFN-I responses is associated with an increased susceptibility of the host to secondary infections. The latter correlates with well- established clinical observations of heightened susceptibility of patients to secondary microbial infections after viral episodes. Immunology and Cell Biology (2008) 86, 239–245; doi:10.1038/sj.icb.7100159; published online 8 January 2008 Keywords: type I interferon; immunoregulation; viral infections Control of viral infections by the vertebrate host involves both the fibroblast (b) and immune (g).2,3 The currently accepted classification innate and the adaptive immune response.
    [Show full text]
  • Accepted Manuscript
    Lawrence Berkeley National Laboratory Recent Work Title CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon- driven inflammation possibly related to the presence of a pathobiont. Permalink https://escholarship.org/uc/item/7qv434pj Authors Shulzhenko, Natalia Dong, Xiaoxi Vyshenska, Dariia et al. Publication Date 2018-12-01 DOI 10.1016/j.clim.2018.09.008 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Accepted Manuscript CVID enteropathy is characterized by exceeding low mucosal iga levels and interferon-driven inflammation possibly related to the presence of a pathobiont Natalia Shulzhenko, Xiaoxi Dong, Dariia Vyshenska, Renee L. Greer, Manoj Gurung, Stephany Vasquez-Perez, Ekaterina Peremyslova, Stanislav Sosnovtsev, Martha Quezado, Michael Yao, Kim Montgomery-Recht, Warren Strober, Ivan J. Fuss, Andrey Morgun PII: S1521-6616(18)30294-8 DOI: doi:10.1016/j.clim.2018.09.008 Reference: YCLIM 8102 To appear in: Clinical Immunology Received date: 25 April 2018 Revised date: 2 August 2018 Accepted date: 16 September 2018 Please cite this article as: Natalia Shulzhenko, Xiaoxi Dong, Dariia Vyshenska, Renee L. Greer, Manoj Gurung, Stephany Vasquez-Perez, Ekaterina Peremyslova, Stanislav Sosnovtsev, Martha Quezado, Michael Yao, Kim Montgomery-Recht, Warren Strober, Ivan J. Fuss, Andrey Morgun , CVID enteropathy is characterized by exceeding low mucosal iga levels and interferon-driven inflammation possibly related to the presence of a pathobiont. Yclim (2018), doi:10.1016/j.clim.2018.09.008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson Et Al
    US 20160367695A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson et al. (43) Pub. Date: Dec. 22, 2016 (54) POLYPEPTIDE CONSTRUCTS AND USES (30) Foreign Application Priority Data THEREOF Oct. 28, 2011 (AU) ................................ 2011 9045O2 (71) Applicant: Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park (AU) Publication Classification (72) Inventors: David S. Wilson, Freemont, CA (US); Sarah L. Pogue, Freemont, CA (US); (51) Int. Cl. Glen E. Mikesell, Pacifica, CA (US); A6II 47/48 (2006.01) Tetsuya Taura, Palo Alto, CA (US); C07K 6/28 (2006.01) Wouter Korver, Mountain View, CA (52) U.S. Cl. (US); Anthony G. Doyle, Drummoyne CPC ..... A61K 47/48269 (2013.01); C07K 16/2896 (AU); Adam Clarke, Five Dock (AU); (2013.01); C07K 231 7/565 (2013.01); C07K Matthew Pollard, Dural (AU): 2317/55 (2013.01); C07K 2317/92 (2013.01) Stephen Tran, Strathfield South (AU); Jack Tzu Chiao Lin, Redwood City, (57) ABSTRACT CA (US) (21) Appl. No.: 15/194,926 The present invention provides a polypeptide construct (22) Filed: Jun. 28, 2016 comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which Related U.S. Application Data binds to a cell Surface-associated antigen, wherein the ligand (63) Continuation of application No. 14/262,841, filed on comprises at least one amino acid Substitution or deletion Apr. 28, 2014, which is a continuation of application which reduces its potency on cells lacking expression of said No. PCT/AU2012/001323, filed on Oct. 29, 2012. antigen. Patent Application Publication Dec.
    [Show full text]
  • WO 2010/142017 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 16 December 2010 (16.12.2010) WO 2010/142017 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) A61P 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 31/00 (2006.01) A61K 38/21 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/CA20 10/000844 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 8 June 2010 (08.06.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/185,261 9 June 2009 (09.06.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): DE- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, FYRUS, INC .
    [Show full text]
  • Multiple Regulatory Regions on the 5' Side of the Mouse Ea Gene
    Proc. Nad. Acad. Sci. USA Vol. 85, pp. 3075-3079, May 1988 Immunology Multiple regulatory regions on the 5' side of the mouse Ea gene (major histocompatibility genes/y-interferon/y-interferon response region) DIMITRIS THANOS*, GEORGE MAVROTHALASSITIS*, AND JOSEPH PAPAMATHEAKIS*t *Institute of Molecular Biology and Biotechnology, Research Center of Crete, P.O. Box 1527, and tDepartment of Biology, University of Crete, 711 10 Heraklion, Crete, Greece Communicated by Fotis C. Kafatos, December 10, 1987 ABSTRACT The function of the 5'-flanking region of the motifs in the 5'-flanking region of all major histocompatibil- mouse major histocompatibility complex gene E4 has been ity complex class II genes (15, 16). We provide evidence that studied by deletion analysis with the chloramphenicol acetyl- the CS are elements necessary for the inducibility by IFN-y. transferase gene as a transient expression marker in various cell lines. This analysis reveals the presence of several control regions on the 5' side of the gene. Sequences between base pair MATERIALS AND METHODS (bp) -873 and bp -353 have a negative function in human Plasmid Constructions. The following vectors were used and mouse fibroblasts but not in the mouse macrophage line for cloning Ea and E1n gene fragments. pL51CAT was derived WEHI-3. Additional positive and negative elements have been from pSV2CAT (17) by replacing the 350-base-pair (bp) Acc mapped between bp - 353 and bp - 38. A V-interferon I-Sph I fragment by a pUC19 polylinker. pLSVOCAT was response region has been also identified within that sequence. derived from pL51CAT by elimination of the 150-bp Sma I The 5' and 3' boundaries of the -interferon response region (polylinker)-HindIII fragment.
    [Show full text]
  • Enhanced Expression of Type I Interferon and Toll-Like Receptor-3 in Primary Biliary Cirrhosis
    Laboratory Investigation (2005) 85, 908–920 & 2005 USCAP, Inc All rights reserved 0023-6837/05 $30.00 www.laboratoryinvestigation.org Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis Yasushi Takii1,3, Minoru Nakamura1,2, Masahiro Ito1,2, Terufumi Yokoyama1, Atsumasa Komori1,2, Yuki Shimizu-Yoshida1, Rumiko Nakao1, Koichiro Kusumoto1,2, Shinya Nagaoka1,2, Koji Yano1,2, Seigo Abiru1,2, Toshihito Ueki1,2, Takehiro Matsumoto1,2, Manabu Daikoku1,2, Ken Taniguchi1,2, Hikaru Fujioka1,2, Kiyoshi Migita1,2, Hiroshi Yatsuhashi1,2, Masahiro Nakashima4, Mine Harada3 and Hiromi Ishibashi1,2 1Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan; 2Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; 3Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan and 4Tissue and Histopathology Section, Division of Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan The pathogenesis of primary biliary cirrhosis (PBC) remains enigmatic. In order to address this issue, we analyzed by laser capture microdissection and real-time reverse transcription-polymerase chain reaction the site-specific expression of messenger RNA (mRNA) for cytokines (interferon (IFN)-a,-b,-c, interleukin (IL)-1b, -4, -6, -10, -12p40, -18, tumor necrosis factor-a) and toll-like receptors (TLRs) (TLR-2, -3, -4, -7, -9) in portal tract and liver parenchyma from patients with early-stage PBC. Expression of IFN-a,-b and TLR-3 proteins was also studied by immunohistochemistry. Autoimmune hepatitis (AIH) and chronic hepatitis C (CHC) served as disease controls.
    [Show full text]
  • Regulation of Type I Interferons in Health and Autoimmune Disease
    Regulation of type I interferons in health and autoimmune disease Antonios Psarras Submitted in accordance with the requirements for the degree of Doctor of Philosophy (PhD) University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine September 2018 i Intellectual property and publication statements The candidate confirms that the work submitted is his own, except where work which has formed part of jointly-authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated below. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. Chapter 1 includes data from a jointly-authored publication: Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. Psarras A performed the review of literature, critically appraised scientific evidences of the relevant topics and led the writing of the manuscripts. Emery revised the manuscripts for important intellectual content and final approval of the manuscript. Chapter 3 includes data from two jointly-authored publications: El-Sherbiny YM*, Psarras A*, Yusof MYM, Hensor EMA, Tooze R, Doody G, et al. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018;8(1):5793. *joint first author El-Sherbiny YM, Emery P, and Vital EM performed conception and design
    [Show full text]
  • Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector ORIGINAL RESEARCH published: 20 March 2017 doi: 10.3389/fimmu.2017.00285 Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production Julio E. Castañeda-Delgado1,2, Yadira Bastián-Hernandez1,2, Noe Macias-Segura1,3, David Santiago-Algarra1, Jose D. Castillo-Ortiz4, Ana L. Alemán-Navarro1, Pedro Martínez-Tejada5, Leonor Enciso-Moreno1, Yolanda Garcia-De Lira1, Diana Olguín-Calderón1, Leendert A. Trouw 6, Cesar Ramos-Remus7 and Jose A. Enciso-Moreno1* 1 Medical research Unit of Zacatecas, Mexican Institute of Social Security, UIMZ-IMSS, Zacatecas, Mexico, 2 National Council of Science and Technology, CONACYT, Catedras-CONACYT, Zacatecas, Mexico, 3 Departamento de fisiología y Edited by: farmacología, centro de ciencias básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, Aguascalientes, Pietro Ghezzi, Mexico, 4 Unidad de Investigación en Enfermedades Crónico-Degenerativas, Guadalajara, Jalisco, México, 5 General Brighton and Sussex Medical School, Hospital: “Emilio Varela Lujan”, Mexican Institute of Social Security, IMSS, Zacatecas, Mexico, 6 Department of UK Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7 Universidad Autonoma de Guadalajara, Jalisco, México Reviewed by: Consuelo Romero-Sanchez, Universidad El Bosque, Colombia Background: Rheumatoid arthritis (RA) is an inflammatory debilitating disease that Maria Silvia Di Genaro, National University of San Luis, affects the joints in the early and productive phases of an individual’s life. Several cyto- Argentina kines have been linked to the disease pathogenesis and are known to contribute to the Ryan Thwaites, inflammatory state characteristic of RA.
    [Show full text]
  • TREM2 R47H Exacerbates Immune Response in Alzheimer's Disease Brain
    bioRxiv preprint doi: https://doi.org/10.1101/499319; this version posted August 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. TREM2 R47H exacerbates immune response in Alzheimer’s disease brain Olena Korvatska1*, Kostantin Kiianitsa2, Alexander Ratushny3, Mark Matsushita4, Neal Beeman4, Wei-Ming Chien4, J-I Satoh5, Michael O. Dorschner6, C. Dirk Keene6, Theo K. Bammler7, Thomas D. Bird8,9, Wendy H. Raskind1,4,9,10 1 Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA 2 Department of Immunology, University of Washington, Seattle, USA. 3 Seattle Biomedical Research Institute and Institute for Systems Biology, Seattle, USA. 4 Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, USA. 5 Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Tokyo, Japan. 6 Department of Pathology, University of Washington, Seattle, USA. 7 Department of Environmental and Occupational Health Sciences, Seattle, USA. 8 Department of Neurology, University of Washington, Seattle, USA. 9 Geriatric Research, Education and Clinical Center, Veteran Affairs Puget Sound Health Care System, Seattle, USA. 10 Mental Illness Research, Education and Clinical Center, Department of Veteran Affairs, Seattle, USA. *To whom correspondence should be addressed: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/499319; this version posted August 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]